The litigation, titled Mazzarino v. ADMA Biologics, Inc., et al., accuses the company and its executives of violating federal securities laws by withholding material information. Plaintiffs allege that ADMA Biologics utilized channel stuffing to artificially inflate revenue figures and failed to disclose a related party transaction. The lawsuit further contends that the company lacked the internal controls necessary to support its public statements regarding business operations and financial health.
ADMA Biologics Faces Class Action Lawsuit Over Disclosure Claims
Investors who lost more than $100,000 in ADMA Biologics securities between August 9, 2024, and March 25, 2026, face an August 10, 2026, deadline to apply as lead plaintiffs in a pending class action lawsuit filed in the United States District Court for the District of New Jersey.
Legal representatives at Kahn Swick & Foti, LLC are currently evaluating claims for affected shareholders. Investors seeking to participate in the class action or review their legal standing may contact ClaimsFiler for further information regarding the case, No. 26-cv-04793.
Comments (0)
No comments yet. Be the first!